Michele S Woo
Overview
Explore the profile of Michele S Woo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
2830
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yoon S, Shin S, Liu Y, Ballif B, Woo M, Gygi S, et al.
Mol Cell
. 2023 Nov;
83(22):4190.
PMID: 37980093
No abstract available.
2.
Watanabe H, Francis J, Woo M, Etemad B, Lin W, Fries D, et al.
Genes Dev
. 2013 Jan;
27(2):197-210.
PMID: 23322301
The NKX2-1 transcription factor, a regulator of normal lung development, is the most significantly amplified gene in human lung adenocarcinoma. To study the transcriptional impact of NKX2-1 amplification, we generated...
3.
Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, et al.
Nature
. 2012 Mar;
483(7391):613-7.
PMID: 22425996
Targeted therapies have demonstrated efficacy against specific subsets of molecularly defined cancers. Although most patients with lung cancer are stratified according to a single oncogenic driver, cancers harbouring identical activating...
4.
Bass A, Watanabe H, Mermel C, Yu S, Perner S, Verhaak R, et al.
Nat Genet
. 2009 Oct;
41(11):1238-42.
PMID: 19801978
Lineage-survival oncogenes are activated by somatic DNA alterations in cancers arising from the cell lineages in which these genes play a role in normal development. Here we show that a...
5.
Yoon S, Shin S, Liu Y, Ballif B, Woo M, Gygi S, et al.
Mol Cell
. 2008 Feb;
29(3):362-75.
PMID: 18280241
The major participants of the Ras/ERK and PI3-kinase (PI3K) pathways are well characterized. The cellular response to activation of these pathways, however, can vary dramatically. How differences in signal strength,...
6.
Yun C, Mengwasser K, Toms A, Woo M, Greulich H, Wong K, et al.
Proc Natl Acad Sci U S A
. 2008 Jan;
105(6):2070-5.
PMID: 18227510
Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small molecule tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is...
7.
Weir B, Woo M, Getz G, Perner S, Ding L, Beroukhim R, et al.
Nature
. 2007 Nov;
450(7171):893-8.
PMID: 17982442
Somatic alterations in cellular DNA underlie almost all human cancers. The prospect of targeted therapies and the development of high-resolution, genome-wide approaches are now spurring systematic efforts to characterize cancer...
8.
Yuza Y, Glatt K, Jiang J, Greulich H, Minami Y, Woo M, et al.
Cancer Biol Ther
. 2007 May;
6(5):661-7.
PMID: 17495523
Targeted cancer therapies impede cancer cell growth by inhibiting the function of activated oncogene products. Patients with non-small cell lung cancer and somatic mutations of EGFR can have a dramatic...
9.
Yun C, Boggon T, Li Y, Woo M, Greulich H, Meyerson M, et al.
Cancer Cell
. 2007 Mar;
11(3):217-27.
PMID: 17349580
Mutations in the EGFR kinase are a cause of non-small-cell lung cancer. To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R...
10.
Woo M, Ohta Y, Rabinovitz I, Stossel T, Blenis J
Mol Cell Biol
. 2004 Mar;
24(7):3025-35.
PMID: 15024089
The Ras-mitogen-activated protein (Ras-MAP) kinase pathway regulates various cellular processes, including gene expression, cell proliferation, and survival. Ribosomal S6 kinase (RSK), a key player in this pathway, modulates the activities...